The FDA's Oncologic Drugs Advisory Committee has voted 8-4 in favor of the use of Amgen's Blincyto, or blinatumomab, as a treatment for patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia. The supplemental biologics license application was backed by data from a midstage study, in which 69 of 116 patients in the study achieved a complete MRD response within the first cycle of blinatumomab treatment.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.